• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ImmunoGen presents data from IMGN779 study in acute myeloid leukemia

ImmunoGen presents data from IMGN779 study in acute myeloid leukemia

June 26, 2017
CenterWatch Staff

ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, presented data from the ongoing phase I study evaluating single agent IMGN779 in patients with relapsed or refractory adult acute myeloid leukemia (AML) whose tumors express CD33. The first-in-human data demonstrate the safety and tolerability of IMGN779 across seven dose levels, with no dose limiting toxicities (DLTs), as well as evidence of dose-dependent biological and anti-leukemia activity.

IMGN779 combines a high-affinity, humanized anti-CD33 antibody with one of ImmunoGen’s novel indolino-benzodiazepine payloads, called IGNs, which alkylate DNA without crosslinking, resulting in potent anti-leukemia activity with relative sparing of normal hematopoietic progenitor cells.

Safety, pharmacokinetic (PK), and pharmacodynamic (PD) data, as well as initial anti-leukemia activity for IMGN779 through dose level seven were presented at EHA. Key findings included:

  • No DLTs have been observed through dose level seven, with reported adverse events consistent with the underlying disease.
  • No increase in the nature, frequency, or severity of any treatment-emergent adverse event has been reported with escalating doses and no evidence of cumulative toxicity has been observed with repeated dosing.
  • Favorable PK/PD reveal prolonged exposure and CD33 saturation at dose levels six and seven.
  • Initial anti-leukemia activity was observed at dose levels six and seven in patients who failed intensive frontline therapy.

The phase I trial is designed to establish the maximum tolerated dose and determine the recommended phase II dose for IMGN779 administered as monotherapy. The trial is also intended to evaluate safety and tolerability and characterize PK, PD and preliminary anti-leukemia activity in relapsed or refractory AML. Dose escalation continues.

“We have designed our DNA-alkylating IGNs to be ultra-potent while providing the tolerability necessary for ongoing retreatment,” said Richard Gregory, Ph.D., executive vice president and chief scientific officer of ImmunoGen. “We believe that by combining IGNs with our ADC technology, we may be able to treat a number of additional cancers that don’t respond to existing ADC therapies. These data suggest favorable tolerability and encouraging activity in patients with AML, and we look forward to determining the recommended dose for IMGN779 and moving quickly into later-stage development.” 

Preclinical data for IMGN779 were also presented at EHA showing the agent is highly active in multiple AML xenograft models and is well-tolerated in preclinical repeat dosing regimens. Findings from the preclinical evaluation provided the foundation for the clinical evaluation of IMGN779 in AML.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing